NCT02470091 2024-01-22
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Children's Oncology Group
Phase 2 Completed
Clinical Trials
3 trialsNCT03382574 2022-06-14
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Terminated
NCT04550949 2020-09-22
To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown